Results 121 to 130 of about 30,137 (282)
The Effect of Ecopipam on the Pharmacokinetics of Concomitant Medications
Clinical and Translational Science, Volume 19, Issue 2, February 2026.ABSTRACT Ecopipam is a first‐in‐class dopamine D1 receptor antagonist under investigation for the treatment of Tourette syndrome. This open‐label, fixed‐sequence, three‐cohort study evaluated whether ecopipam induces or inhibits cytochrome P450 (CYP) 1A2, CYP2B6, CYP2C19, CYP2D6, CYP3A4, organic anion‐transporting polypeptide (OATP) 1B1, and p ...
Virginia D. Schmith +4 more
wiley +1 more source
Could a neurological disease be a part of Mozart’s pathography? [Neurološki aspekt Mozartove patografije] [PDF]
, 2011 As expected, since we recently celebrated the 250th anniversary of birth of Wolfgang Amadeus Mozart, there has been again a renewal of interest in his short but intensive life, as well as in the true reason of his untimely dead.
Erdeljić, Viktorija, Ivkić, Goran
core
Developmental Medicine &Child Neurology, Volume 68, Issue 2, Page 263-275, February 2026.The incidence of developmental disorders and special educational needs (SEN) provision were investigated, and associations with gestational age and ethnicity were explored, using the Born in Bradford cohort. Birth before full term was associated with increased odds of developmental disorder and/or SEN, which was even demonstrated in early term (37–38 ...
Katherine Pettinger +4 more
wiley +1 more source
Deep Brain Stimulation of the H Fields of Forel Alleviates Tics in Tourette Syndrome
Frontiers in Human Neuroscience, 2017 The current rationale for target selection in Tourette syndrome revolves around the notion of cortico-basal ganglia circuit involvement in the pathophysiology of the disease.
Clemens Neudorfer +5 more
doaj +1 more source
Developmental Medicine &Child Neurology, Volume 68, Issue 2, Page 251-262, February 2026.In children potentially fulfilling the criteria for developmental coordination disorder (DCD), phenotypical assessment does not sufficiently predict the diagnostic outcome (i.e. DCD or an alternative diagnosis). Due to the lack of distinguishing clinical and diagnostic features and the high prevalence of genetic diagnoses in these patients, additional ...
Martinica Garofalo +5 more
wiley +1 more source
Behavioural Neurology, 2013 Background: Gilles de la Tourette syndrome (GTS) is a chronic childhood-onset neuropsychiatric disorder with a significant impact on patients’ health-related quality of life (HR-QOL). Cavanna et al. (Neurology 2008; 71: 1410–1416) developed and validated
Andrea E. Cavanna +11 more
doaj +1 more source
Georges Gilles de la Tourette and his legacy
Archives of Medicine and Health Sciences, 2019 The first comprehensive description of Gilles de la Tourette syndrome as a neurological condition dates back to 1885 when Georges Gilles de la Tourette (1857–1904) published his case series of nine patients sharing the clinical triad of tics, echolalia ...
Andrea E Cavanna, Stefano Seri
doaj +1 more source
Contribution of therapeutic strategies for understanding the Tourette syndrome [PDF]
, 2015 Luc Mallet +3 more
openalex +1 more source
European clinical guidelines for Tourette syndrome and other tic disorders—version 2.0. Part III: pharmacological treatment [PDF]
, 2021 Veit Roessner +18 more
openalex +1 more source
Glutamate Delta 1 Receptor in Synapses, Circuits, and Disease
European Journal of Neuroscience, Volume 63, Issue 3, February 2026.This review discusses our current understanding of the structure–function, expression and roles in neural circuits of the less studied glutamate delta 1 (GluD1) receptor. Converging data suggests many unique features of GluD1 including expression at both excitatory and inhibitory synapses and binding to D‐serine and GABA.
Diane Choi +3 more
wiley +1 more source